E. Ehrnrooth

2.5k citations

57 papers · 1.7k indexed · h-index 17

Otorhinolaryngology top 1%
- Head and Neck Cancer Studies 8
Oncology top 5%
- Lung Cancer Research Studies 13
- HER2/EGFR in Cancer Research 11
- Cancer Immunotherapy and Biomarkers 10
- Colorectal Cancer Treatments and Studies 7
- Peptidase Inhibition and Analysis 5
Immunology top 10%
- Immunotherapy and Immune Responses 8
Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations 31
Family Practice top 10%

Co-authors: Hans von der Maase Philip Rossen Charlotte Gjørup Pedersen Robert Zachariae Anders Bonde Jensen Ezra E.W. Cohen Mai-Britt Zocca Jérôme Fayette
Cited by: Otorhinolaryngology Oncology Immunology
Journals: Journal of Clinical Oncology (12 papers)Annals of Oncology (11 papers)Journal of Thoracic Oncology (4 papers)
Partner nations: United States Denmark Spain

In The Last Decade

E. Ehrnrooth

56 papers receiving 1.7k citations

Peers

Countries citing papers authored by E. Ehrnrooth

Since Specialization

Citations

This map shows the geographic impact of E. Ehrnrooth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Ehrnrooth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Ehrnrooth more than expected).

Fields of papers citing papers by E. Ehrnrooth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Ehrnrooth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Ehrnrooth. The network helps show where E. Ehrnrooth may publish in the future.

Co-authorship network

The 25 scholars most cited alongside E. Ehrnrooth, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with E. Ehrnrooth Line = papers co-authored together E. Ehrnrooth links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	1038P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN) Annals of Oncology ·Jonathan W. Riess,Ezra E.W. Cohen,James Spicer,Peter H. Shaw,位田文香,Diana Carolina Mira Tamayo,Marya Chaney,Shane O’Neill,Ayako Wakatsuki Pedersen,Dermot T. McDowell,E. Ehrnrooth,Pilar Garrido	2023	1
2	Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial Frontiers in Immunology ·Cathrine Lund Lorentzen,Evelina Martinenaite,Julie Westerlin Kjeldsen,Rikke B. Holmstroem,Тоом Андрей Леонович,Ayako Wakatsuki Pedersen,E. Ehrnrooth,Mads Hald Andersen,Inge Marie Svane	2022	36
3	A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma Nature Medicine ·Julie Westerlin Kjeldsen,Cathrine Lund Lorentzen,Evelina Martinenaite,Eva Ellebæk,Marco Donia,Rikke B. Holmstroem,Tobias Wirenfeldt Klausen,F. V. Kusmartsev,P. H. Sales De Bruin,Stine Emilie Weis-Banke,Morten Orebo Holmström,Helle Westergren Hendel,E. Ehrnrooth,Mai-Britt Zocca,Ayako Wakatsuki Pedersen,Mads Hald Andersen,Inge Marie Svane	2021	135
4	Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study Cancers ·Ehab S. Billatos,Jeanette Kaae,Amrita Sharma,Özcan Met,Signe Ledou Nielsen,Ayako Wakatsuki Pedersen,Inge Marie Svane,E. Ehrnrooth,Mads Hald Andersen,Claus Zachariae,Lone Skov	2021	10
5	First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials Lung Cancer ·Martin Schüler,Luis Paz‐Ares,Lecia V. Sequist,Vera Hirsh,Ki Hyeong Lee,Yi‐Long Wu,Shun Lü,Caicun Zhou,Jifeng Feng,Stuart H. Ellis,S. Perl,Wenbo Tang,Angela Märten,E. Ehrnrooth,Keunchil Park,James Chih‐Hsin Yang	2019	23
6	P2.01-12 A Phase I/II Trial of IO102 and Pembrolizumab With/Without Chemotherapy as First-line Treatment of Metastatic NSCLC Journal of Thoracic Oncology ·Mariano Provencio,James Spicer,Pilar Garrido,J.M. Trigo Perez,Santiago Viteri,Joaquim Bosch‐Barrera,Amelia Insa,Enriqueta Felip,Ralph Ferraro,Seyedhossein Hosseini,Emmett V. Schmidt,Anita Vedel Christiansen,Patrick Karl O'Brien,Mai-Britt Zocca,E. Ehrnrooth,Greg Welty	2019	1
7	Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7 Annals of Oncology ·Lecia V. Sequist,Yi‐Long Wu,Martin Schüler,Terufumi Kato,J.C.-H. Yang,Hiroshi Tanaka,Toyoaki Hida,Shun Lü,Lencevicius,Scott A. Laurie,Jaafar Bennouna,Lilian A. Paim,Angela Märten,Barbara Peil,E. Ehrnrooth,Nobuyuki Yamamoto,Kazuhiko Nakagawa	2017	10
8	Afatinib in patients with advanced or metastatic urothelial carcinoma (UC) with genetic alterations in ErbB receptors 1–3 who failed on platinum-based chemotherapy: The Phase II LUX-Bladder 1 trial Annals of Oncology ·Albert Font,Francisco X. Real,Javier Puente,Kalin Guanlun Lai,Núria Sala,Juan Antonio Virizuela,Alejo Rodríguez‐Vida,Enrique Grande Pulido,Daniel Castellano,José A. Martínez-Climent,Raquel Justo González,Aranzazu González del Alba,Pedro L. Fernández,Pedro Jares,Ibán Aldecoa,Neil Gibson,修平深見,René Rodríguez-Gutiérrez,E. Ehrnrooth,Begoña Mellado	2017	2
9	LUX-Lung 8 phase III trial: Analysis of long-term response to second-line afatinib in patients with advanced squamous cell carcinoma (SCC) of the lung Annals of Oncology ·James Chih‐Hsin Yang,Glen Goss,Enriqueta Felip,Shun Lü,Andrea Ardizzoni,Shirish M. Gadgeel,V. Georgoulias,Nicholas Dupuis,E. Ehrnrooth,J.C. Soria	2017	3
10	Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy Clinical Lung Cancer ·Enriqueta Felip,Vera Hirsh,Sanjay Popat,Manuel Cobo,Andrea Fülöp,C. Dayen,José Trigo,Richard Gregg,Cornelius F. Waller,Jean‐Charles Soria,Glenwood Goss,J Gordon,Bushi Wang,Michael Palmer,E. Ehrnrooth,Shirish M. Gadgeel	2017	25
11	Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung Annals of Oncology ·Glenwood Goss,K.H. Lee,Enriqueta Felip,Manuel Cobo,خنوس محمد الهادي,Erdem Göker,张玉娟,(unknown),Dolores Isla,Young Joo Min,Alessandro Morabito,Nicholas Dupuis,Vikram K. Chand,Flavio Solca,Nicole Krämer,Neil Gibson,E. Ehrnrooth,J.C. Soria	2016	1
12	Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial Annals of Oncology ·Paul M. Clément,Thomas Gauler,J.-P. Machiels,Robert I. Haddad,Jérôme Fayette,Lisa Licitra,Makoto Tahara,Ezra E.W. Cohen,Didier Cupissol,Juan J. Grau,J. Guigay,Francesco Caponigro,Gilberto de Castro,Luciano de Souza Viana,Ulrich Keilholz,J.M. del Campo,Xiuyu Julie Cong,E. Ehrnrooth,Jan B. Vermorken	2016	31
13	A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck Annals of Oncology ·Tanguy Y. Seiwert,Jérôme Fayette,Didier Cupissol,J.M. del Campo,Paul M. Clément,Ricardo Hitt,M. Degardin,Thomas Cargill,C.,E. Ehrnrooth,Ezra E.W. Cohen	2014	138
14	A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors Annals of Oncology ·Jan B. Vermorken,Sylvie Rottey,E. Ehrnrooth,富英西田,Е. С. Олексюк,Sven Wind,J-P. Machiels	2013	31
15	In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics Cytokine ·Kresten Skak,Henrik Søndergaard,Klaus Stensgaard Frederiksen,E. Ehrnrooth	2009	4
16	Rectal cancer survival in the Nordic countries and Scotland International Journal of Cancer ·Joakim Folkesson,Gerda Engholm,E. Ehrnrooth,Nobuo Tsujinaka,Lars Påhlman,Henrik Harling,Arne Wibe,Maria Gaard,Taner Acikalin,Laufey Tryggvadóttír,David Brewster,Timo Hakulinen,Hans H. Storm	2009	21
17	Third-line therapy for metastatic colorectal cancer Cancer Chemotherapy and Pharmacology ·Maria Gry Gundgaard,光山倫央,E. Ehrnrooth	2007	6
18	Increased Thymidylate Synthase mRNA Concentration in Blood Leukocytes following an Experimental Stressor Psychotherapy and Psychosomatics ·E. Ehrnrooth,眞野惠子,Andrew Barron,K. A. Day,S.V. MARIHIN,Boe Sandahl Sørensen,Jørgen Poulsen,Hans von der Maase	2002	5
19	A new quantitative RT–PCR assay for thymidylate synthase mRNA in blood leukocytes applied to cancer patients and healthy controls Clinica Chimica Acta ·E. Ehrnrooth,Boe Sandahl Sørensen,Peter Meldgaard,Nete Hornung,Jørgen Poulsen,Hans von der Maase	2000	3
20	The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors International Journal of Radiation OncologyBiologyPhysics ·Michael R. Horsman,E. Ehrnrooth,Morten Ladekarl,Jens Overgaard	1998	82

About E. Ehrnrooth

E. Ehrnrooth is a scholar working on Otorhinolaryngology, Oncology, Pulmonary and Respiratory Medicine, Biotechnology and Biological Psychiatry, having authored 57 papers that have together received 1.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (31 papers), Lung Cancer Research Studies (13 papers), HER2/EGFR in Cancer Research (11 papers), Cancer Immunotherapy and Biomarkers (10 papers), Immunotherapy and Immune Responses (8 papers), Head and Neck Cancer Studies (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Peptidase Inhibition and Analysis (5 papers). The work is most often cited by research in Otorhinolaryngology (312 citations), Oncology (861 citations), Immunology (354 citations), Pulmonary and Respiratory Medicine (510 citations) and Family Practice (34 citations). E. Ehrnrooth has collaborated with scholars based in United States, Denmark and Spain. Frequent co-authors include Hans von der Maase, Philip Rossen, Charlotte Gjørup Pedersen, Robert Zachariae, Anders Bonde Jensen, Ezra E.W. Cohen, Mai-Britt Zocca, Jérôme Fayette, Didier Cupissol and Paul M. Clément. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, European Journal of Cancer and International Journal of Radiation Oncology*Biology*Physics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact